Effects of Psilocybin in Major Depressive Disorder
Brief Summary
The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. The primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.
Study Design
Study type: | Interventional |
---|---|
Status: | Completed |
Study results: | Has Results |
Age: | 21 Years to 75 Years (Adult, Older Adult) |
Enrollment: | 27 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Aug 10, 2017 | |
---|---|---|
Primary Completion: | Dec 02, 2020 | |
Completion Date: | Dec 02, 2020 | |
Study First Posted: | Jun 08, 2017 | |
Results First Posted: | Dec 15, 2021 | |
Last Updated: | Dec 15, 2021 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 21 |
Maximum Age: | 75 |
More Details
NCT Number: | NCT03181529 |
---|---|
Other IDs: | IRB00101821 |
Study URL: | https://ClinicalTrials.gov/show/NCT03181529 |
Last updated: Jun 16, 2022